Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
Kriya Therapeutics has raised $320.8M in total funding. The most recent round was Series D. The last funding was announced in August 2025.
Kriya Therapeutics's investors include Alumni Ventures, Foresite Capital, Patient Square Capital, Amplo, Narya Capital.
Kriya Therapeutics is headquartered in Palo Alto, United States.
Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
Kriya Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kriya Therapeutics — Funding & Investors." VCBacked, August 15, 2025, https://www.vcbacked.co/company/kriya-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Kriya Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/kriya-therapeutics
{{cite web |title=Kriya Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kriya-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated